- Home
- MRNA vs REG Comparison
MRNA vs REG Comparison
Compare MRNA & REG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRNA
- REG
- Stock Information
- Founded
- MRNA 2010
- REG 1963
- Country
- MRNA United States
- REG United States
- Employees
- MRNA N/A
- REG N/A
- Industry
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- REG Real Estate Investment Trusts
- Sector
- MRNA Health Care
- REG Real Estate
- Exchange
- MRNA Nasdaq
- REG Nasdaq
- Market Cap
- MRNA 10.9B
- REG 13.1B
- IPO Year
- MRNA 2018
- REG 1993
- Fundamental
- Price
- MRNA $25.87
- REG $70.13
- Analyst Decision
- MRNA Hold
- REG Buy
- Analyst Count
- MRNA 19
- REG 13
- Target Price
- MRNA $43.50
- REG $78.46
- AVG Volume (30 Days)
- MRNA 12.2M
- REG 1.1M
- Earning Date
- MRNA 11-06-2025
- REG 10-27-2025
- Dividend Yield
- MRNA N/A
- REG 4.03%
- EPS Growth
- MRNA N/A
- REG 2.52
- EPS
- MRNA N/A
- REG 2.14
- Revenue
- MRNA $3,078,000,000.00
- REG $1,547,928,000.00
- Revenue This Year
- MRNA N/A
- REG $1.98
- Revenue Next Year
- MRNA $10.17
- REG $4.11
- P/E Ratio
- MRNA N/A
- REG $32.73
- Revenue Growth
- MRNA N/A
- REG 6.08
- 52 Week Low
- MRNA $23.15
- REG $63.44
- 52 Week High
- MRNA $75.37
- REG $78.18
- Technical
- Relative Strength Index (RSI)
- MRNA 51.44
- REG 38.37
- Support Level
- MRNA $23.18
- REG $71.84
- Resistance Level
- MRNA $25.90
- REG $71.14
- Average True Range (ATR)
- MRNA 1.16
- REG 1.01
- MACD
- MRNA 0.27
- REG -0.35
- Stochastic Oscillator
- MRNA 95.05
- REG 12.02
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
About REG Regency Centers Corporation
Regency Centers is one of the largest shopping center-focused retail REITs. The company's portfolio includes an interest in 482 properties, which includes over 57 million square feet of retail space following the completion of the Urstadt Biddle acquisition in August 2023. The portfolio is geographically diversified with 22 regional offices and no single market representing more than 12% of total company net operating income. Regency's retail portfolio is primarily composed of grocery-anchored centers, with 80% of properties featuring a grocery anchor and grocery stores representing 20% of annual base rent.